Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Epistemonikos ID: 7d97cac03b5b56c2266d8eb82c196d8f7b1ad52a
First added on: Aug 19, 2026